Hipfest 2024: International Hip-hop Culture Festival Explodes In Vietnam
HO CHI MINH CITY, Vietnam, Dec. 9, 2024 /PRNewswire/ — December 14-15, 2024, at Saigon Riverside Park, Hipfest 2024 festival – organized by the Viet Nam Union of Friendship Organizations, and Enter CEC Company Limited, will officially take place, marking the 9th season of the largest
Globally top 5%, Astronergy won greater-value EcoVadis group scope gold rating
HANGZHOU, China, Dec. 9, 2024 /PRNewswire/ — Astronergy, full name in Chint New Energy Technology Co.,Ltd., has received a group-level gold medal from EcoVadis, placing the company among the 5% best enterprises evaluated globally in Environment, Labor and human rights, Ethics and Sustainable P
Moloco Strengthens Asia Pacific Footprint with Key Leadership Hires
Nopparat Yokubon and Jason Bagg Join Moloco to Drive Regional Growth SINGAPORE, Dec. 9, 2024 /PRNewswire/ — Moloco, the leader in operational machine learning (ML) and performance advertising, announced the appointments of Nopparat Yokubon, as Moloco Ads Lead for Southeast Asia (SEA), Australi
Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH
BEIJING, SHANGHAI and BOSTON, Dec. 8, 2024 /PRNewswire/ — Jacobio Pharma (1167.HK), a clinical-stage oncology company dedicated to developing therapies toward undruggable targets, today presented preliminary Phase I data of BET inhibitor JAB-8263 to treat myelofibrosis (MF) at the 2024 ASH (
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma
New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10-6) with DARZALEX FASPRO® were progression free at 4.5 years Subgroup analysis from Phase 3 AURIGA study show higher rates of MRD-negative conversion in patient populations disproportionately
Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting
CS5001 is so far the first anti-ROR1 ADC known to show clinical anti-tumor activity in both solid tumors and lymphomas. The data presented at ASH highlighted the latest safety and efficacy of CS5001 as a monotherapy for patients with advanced lymphomas. CS5001 is well tolerated in heavily pre-trea
STEERING THE CONVERSATION: MILLENNIALS AND GEN ZS MAKE THE MOST FRIENDSHIPS ON THE BUS
Three in 10 (30%) Brits have made long-lasting friendships with people they have met on the bus Contrary to popular belief, it’s the younger generations who are nattering on the bus the most with half (46%) of Gen Z having made friends in this way 82% of Brits feel public transport plays an
Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024
SAN FRANCISCO and SUZHOU, China, Dec. 8, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metaboli
SYM Investors Have Opportunity to Lead Symbotic Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
NEW YORK, Dec. 8, 2024 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Symbotic Inc. (NASDAQ: SYM) between February 8, 2024 and November 26, 2024, both dates inclusive (the “Class Per
Media Advisory – Deputy Prime Minister’s itinerary for Monday, December 9, 2024
OTTAWA, ON, Dec. 8, 2024 /CNW/ – Note: All times local. Ottawa, Ontario Private meetings. 3:30 p.m. The Deputy Prime Minister will appear before the House of Commons Standing Committee on Industry and Technology. She will be joined by the Minister of Innovation, Science and Industry, Franço